

Title (en)

METHODS FOR THE ADMINISTRATION OF ILOPERIDONE

Title (de)

VERFAHREN ZUR VERABREICHUNG VON ILOPERIDON

Title (fr)

PROCÉDÉS D'ADMINISTRATION DE L'ILOPÉRIDONE

Publication

EP 3492081 A1 20190605 (EN)

Application

EP 18187366 A 20090910

Priority

- US 20802708 A 20080910
- EP 09792421 A 20090910
- US 2009056517 W 20090910

Abstract (en)

The present invention relates to methods for the identification of genetic polymorphisms that may be associated with a risk for QT prolongation after treatment with iloperidone and related methods of administering iloperidone to patients with such polymorphisms.

IPC 8 full level

A61K 31/454 (2006.01); **A61K 31/137** (2006.01); **A61K 31/138** (2006.01); **A61K 31/439** (2006.01); **A61K 31/4525** (2006.01);
A61K 49/00 (2006.01); **A61P 25/00** (2006.01); **A61P 25/18** (2006.01); **A61P 25/24** (2006.01); **G01N 33/50** (2006.01)

CPC (source: EP US)

A61K 31/135 (2013.01 - EP US); **A61K 31/4525** (2013.01 - EP US); **A61K 31/454** (2013.01 - EP US); **A61K 31/496** (2013.01 - EP US);
A61P 9/06 (2018.01 - EP); **A61P 25/00** (2018.01 - EP); **A61P 25/18** (2018.01 - EP US); **A61P 25/22** (2018.01 - EP); **A61P 25/24** (2018.01 - EP);
C12Q 1/6883 (2013.01 - US); **C12Q 2600/106** (2013.01 - US); **C12Q 2600/156** (2013.01 - US)

C-Set (source: EP US)

1. **A61K 31/135 + A61K 2300/00**
2. **A61K 31/4525 + A61K 2300/00**
3. **A61K 31/454 + A61K 2300/00**
4. **A61K 31/496 + A61K 2300/00**

Citation (applicant)

- US 536486 A 19941115 - STRUPCZEWSKI JOSEPH T [US], et al
- WO 03020707 A1 20030313 - NOVARTIS AG [CH], et al
- US 2003083485 A1 20030501 - MILOS PATRICE M [US], et al
- US 2004072235 A1 20040415 - DAWSON ELLIOTT P [US]
- US 2004091909 A1 20040513 - HUANG DOUG HUI [US]
- US 2004096874 A1 20040520 - NEVILLE MATT [GB], et al
- WO 03054226 A2 20030703 - NOVARTIS AG [CH], et al
- US 2003091645 A1 20030515 - AHLHEIM MARKUS [DE], et al
- EP 0307619 W 20030714
- WO 02064141 A1 20020822 - NOVARTIS AG [CH], et al
- US 5846717 A 19981208 - BROW MARY ANN D [US], et al
- US 6001567 A 19991214 - BROW MARY ANN D [US], et al
- WO 03038123 A2 20030508 - NOVARTIS AG [CH], et al
- RYAN ET AL., MOLECULAR DIAGNOSIS, vol. 4, no. 2, 1999, pages 135 - 144
- LYAMICHEV ET AL., NATURE BIOTECHNOLOGY, vol. 17, 1999, pages 292 - 296

Citation (search report)

- [X] WO 2006039663 A2 20060413 - VANDA PHARMACEUTICALS INC [US], et al
- [A] US 2004091909 A1 20040513 - HUANG DOUG HUI [US]
- [A] WO 0059486 A2 200001012 - PFIZER PROD INC [US], et al
- [AP] WO 2008121899 A2 20081009 - VANDA PHARMACEUTICALS INC [US], et al
- [AP] WO 2008144599 A2 20081127 - VANDA PHARMACEUTICALS INC [US], et al
- [A] CACCIA SILVIO: "New antipsychotic agents for schizophrenia: pharmacokinetics and metabolism update.", CURRENT OPINION IN INVESTIGATIONAL DRUGS (LONDON, ENGLAND : 2000) JUL 2002, vol. 3, no. 7, July 2002 (2002-07-01), pages 1073 - 1080, XP008115201, ISSN: 1472-4472
- [A] MUTLIB A E ET AL: "Application of liquid chromatography/mass spectrometry in accelerating the identification of human liver cytochrome P450 isoforms involved in the metabolism of iloperidone", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, AMERICAN SOCIETY FOR PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, US, vol. 386, no. 3, 1 September 1998 (1998-09-01), pages 1285 - 1293, XP002493626, ISSN: 0022-3565

Citation (examination)

LEIF BERTILSSON ET AL: "Molecular genetics of CYP2D6: Clinical relevance with focus on psychotropic drugs : Molecular genetics of CYP2D6", BRITISH JOURNAL OF CLINICAL PHARMACOLOGY., vol. 53, no. 2, 1 February 2002 (2002-02-01), GB, pages 111 - 122, XP055381924, ISSN: 0306-5251, DOI: 10.1046/j.0306-5251.2001.01548.x

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

DOCDB simple family (publication)

US 2010063093 A1 20100311; AU 2009291717 A1 20100318; CA 2736245 A1 20100318; CA 2736245 C 20220712; EP 2331098 A1 20110615;
EP 2331098 B1 20180808; EP 3492081 A1 20190605; ES 2688476 T3 20181102; JP 2012502105 A 20120126; SI 2331098 T1 20181030;
US 2014039008 A1 20140206; US 2016053324 A1 20160225; US 2019360047 A1 20191128; US 2022259660 A1 20220818;
WO 2010030783 A1 20100318

US 20802708 A 20080910; AU 2009291717 A 20090910; CA 2736245 A 20090910; EP 09792421 A 20090910; EP 18187366 A 20090910;
ES 09792421 T 20090910; JP 2011526972 A 20090910; SI 200931877 T 20090910; US 2009056517 W 20090910;
US 201314044183 A 20131002; US 201514847784 A 20150908; US 201916406229 A 20190508; US 202217716968 A 20220408